Kenai Therapeutics Announces the Appointment of Dr. Derek Hei as Chief Technology Officer Portfolio News / By Karina Tin October 23, 2024 Kenai Therapeutics Announces the Appointment of Dr. Derek Hei as Chief Technology Officer Read More »
Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium Portfolio News / By Karina Tin October 23, 2024 Atavistik Bio Presents Preclinical Data on Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor, at EORTC-NCI-AACR Symposium Read More »
Circle’s CID-078, a First-in-Class Oral Macrocycle CyclinA/B-RxL Inhibitor, Demonstrates Anti-Tumor Activity in E2F-driven Cancers Portfolio News / By Karina Tin October 23, 2024 Circle’s CID-078, a First-in-Class Oral Macrocycle CyclinA/B-RxL Inhibitor, Demonstrates Anti-Tumor Activity in E2F-driven Cancers Read More »
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Portfolio News / By Karina Tin October 23, 2024 ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Read More »
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM Portfolio News / By Karina Tin October 17, 2024 Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM Read More »
Circle Pharma announces first patients dosed in Phase 1 clinical trial of first-in-class oral Cyclin A/B RxL inhibitor CID-078 for advanced solid tumors Portfolio News / By Karina Tin October 15, 2024 Circle Pharma announces first patients dosed in Phase 1 clinical trial of first-in-class oral Cyclin A/B RxL inhibitor CID-078 for advanced solid tumors Read More »
Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor Portfolio News / By Karina Tin October 15, 2024 Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor Read More »
Circle Pharma and Boehringer Ingelheim announce new research collaboration to develop a novel precision cancer treatment Portfolio News / By Karina Tin October 9, 2024 Circle Pharma and Boehringer Ingelheim announce new research collaboration to develop a novel precision cancer treatment Read More »
Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney Portfolio News / By Karina Tin October 7, 2024 Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney Read More »
Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO Portfolio News / By Karina Tin October 7, 2024 Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO Read More »
